Abstract
The peptidyl prolyl cis/trans isomerase Pin1, the human ortholog of yeast Ess1 specifically isomerizes peptide bindings of pSer/pThr-Pro residues in various proteins, and regulates the expression levels and functions of phosphorylated proteins. Activation of Pin1 is associated with pathology of a variety of diseases, such as cancer, Alzheimer’s disease, infectious diseases and so on. Therefore, regulatory compounds for Pin1 can be applied as a clinical medicine against these diseases. Many chemists have exerted themselves to synthesize the inhibitors based on the 3D structure of Pin1. We have screened for the inhibitors against Pin1 from the natural products including the functional foods. Here we review the Pin1-associated pathology and the known inhibitors identified from natural products. And we introduce the screening methods targeting Pin1 activity.
Keywords: Inhibitor, natural products, Pin1, screening.
Current Drug Targets
Title:Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products
Volume: 15 Issue: 10
Author(s): Katsuhiko Takahashi, Taiki Shimizu, Keita Kosaka, Masafumi Hidaka, Chiyoko Uchida and Takafumi Uchida
Affiliation:
Keywords: Inhibitor, natural products, Pin1, screening.
Abstract: The peptidyl prolyl cis/trans isomerase Pin1, the human ortholog of yeast Ess1 specifically isomerizes peptide bindings of pSer/pThr-Pro residues in various proteins, and regulates the expression levels and functions of phosphorylated proteins. Activation of Pin1 is associated with pathology of a variety of diseases, such as cancer, Alzheimer’s disease, infectious diseases and so on. Therefore, regulatory compounds for Pin1 can be applied as a clinical medicine against these diseases. Many chemists have exerted themselves to synthesize the inhibitors based on the 3D structure of Pin1. We have screened for the inhibitors against Pin1 from the natural products including the functional foods. Here we review the Pin1-associated pathology and the known inhibitors identified from natural products. And we introduce the screening methods targeting Pin1 activity.
Export Options
About this article
Cite this article as:
Takahashi Katsuhiko, Shimizu Taiki, Kosaka Keita, Hidaka Masafumi, Uchida Chiyoko and Uchida Takafumi, Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140903110724
DOI https://dx.doi.org/10.2174/1389450115666140903110724 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer
Current Genomics Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets New Insights on Fak and Fak Inhibitors
Current Medicinal Chemistry Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Aging and immunopathology in primary Sjögren's syndrome
Current Aging Science MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table)
Current Pharmacogenomics and Personalized Medicine Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
Current Reviews in Clinical and Experimental Pharmacology The N-Terminal Region of HIV-1 Tat Protein Binds CD127 in Human CD8 T Cells to Target the Receptor for Down Regulation Through Tat's Basic Region
Current HIV Research